We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

53 hedge funds and large institutions have $20.6M invested in Theriva Biologics in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

7% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 15

25% less capital invested

Capital invested by funds: $27.4M → $20.6M (-$6.78M)

28% less funds holding

Funds holding: 74 → 53 (-21)

78% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 27

Holders
53
Holders Change
-21
Holders Change %
-28.38%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
14
Reduced
15
Closed
27
Calls
$5.91M
Puts
–
Net Calls
+$5.91M
Net Calls Change
-$682K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$633K
2
Millennium Management
Millennium Management
New York
+$523K
3
ECM
Element Capital Management
New York
+$274K
4
PP
Paloma Partners
Connecticut
+$209K
5
LP
LMR Partners
United Kingdom
+$194K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.52M
2
SM
Sabby Management
Florida
-$712K
3
State Street
State Street
Massachusetts
-$513K
4
Northern Trust
Northern Trust
Illinois
-$478K
5
BCM
Bridgeway Capital Management
Texas
-$228K
Name Holding Trade Value Shares
Change 		Change in
Stake
MAM
51
Meeder Asset Management
Ohio
$4K – – –
Manulife (Manufacturers Life Insurance)
52
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K – – –
SPIA
53
Steward Partners Investment Advisory
New York
$2K – – –
TWA
54
TCI Wealth Advisors
Arizona
$2K – – –
Citigroup
55
Citigroup
New York
$1K – – –
KF
56
Krilogy Financial
Missouri
$1K – – –
VCM
57
Vivaldi Capital Management
Illinois
$54 +$24.9K +5 +83%
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
$12 -$4.98K -1 Closed
BCM
59
Bridgeway Capital Management
Texas
– -$228K -41 Closed
TCIM
60
TIAA CREF Investment Management
New York
– -$162K -29 Closed
California State Teachers Retirement System (CalSTRS)
61
California State Teachers Retirement System (CalSTRS)
California
– -$127K -23 Closed
TA
62
Teachers Advisors
New York
– -$76K -14 Closed
Charles Schwab
63
Charles Schwab
California
– -$75K -13 Closed
RhumbLine Advisers
64
RhumbLine Advisers
Massachusetts
– -$59K -11 Closed
PPA
65
Parametric Portfolio Associates
Washington
– -$52K -9 Closed
ARTA
66
A.R.T. Advisors
New York
– -$39K -7 Closed
JP Morgan Chase
67
JP Morgan Chase
New York
– -$38K -7 Closed
LCM
68
Landscape Capital Management
New Jersey
– -$34K -6 Closed
AIG
69
American International Group
New York
– -$30K -5 Closed
MLM
70
Mount Lucas Management
Pennsylvania
– -$28K -5 Closed
NFA
71
Nationwide Fund Advisors
Ohio
– -$30K -5 Closed
D.E. Shaw & Co
72
D.E. Shaw & Co
New York
– -$21K -4 Closed
Deutsche Bank
73
Deutsche Bank
Germany
– -$19.9K -4 Closed
New York State Common Retirement Fund
74
New York State Common Retirement Fund
New York
– -$21K -4 Closed
VOYA Investment Management
75
VOYA Investment Management
Georgia
– -$24K -4 Closed
1 2
3
4

TOVX Hedge Fund Activity: Q2 2017 in Review

53 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2017, worth a combined $20.6M — down 25% from $27.4M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of TOVX and 6 opened new positions — a net loss of 21 holders — while 15 trimmed existing stakes and 14 added.

The largest buyer was Goldman Sachs, adding an estimated $633K. The largest seller was BlackRock, cutting an estimated $2.52M.

  • 53 institutional investors held Theriva Biologics (TOVX) as of Q2 2017, down from 74 in Q1 2017.
  • Funds reported $20.6M of Theriva Biologics stock for Q2 2017, down 25% quarter-over-quarter.
  • 6 funds opened new Theriva Biologics positions in Q2 2017 and 27 closed out, a net change of -21 holders.
  • The largest Theriva Biologics buyer in Q2 2017 was Goldman Sachs, an estimated $633K added.
  • The largest Theriva Biologics seller in Q2 2017 was BlackRock, an estimated $2.52M sold.

Based on aggregated 13F filings for Q2 2017.